<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Tumor microenvironment immunology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tumor-microenvironment-immunology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 16 Sep 2025 17:41:49 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Tumor microenvironment immunology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>PPARγ Drives OSCC Growth Through Th17 and CEBPA</title>
		<link>https://bioengineer.org/ppar%ce%b3-drives-oscc-growth-through-th17-and-cebpa/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 16 Sep 2025 17:41:45 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CEBPA signaling pathways]]></category>
		<category><![CDATA[IL-17C oncogenic role]]></category>
		<category><![CDATA[PPARγ in OSCC progression]]></category>
		<category><![CDATA[Th17 cell polarization]]></category>
		<category><![CDATA[Tumor microenvironment immunology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ppar%ce%b3-drives-oscc-growth-through-th17-and-cebpa/</guid>

					<description><![CDATA[Recent advances in cancer research have spotlighted the role of PPARγ, or Peroxisome Proliferator-Activated Receptor Gamma, in the progression of Oral Squamous Cell Carcinoma (OSCC). This hormone-activated transcription factor, known for its involvement in lipid metabolism and glucose homeostasis, has now been identified as a critical player in the malignant transformation of oral epithelial cells. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">269663</post-id>	</item>
		<item>
		<title>Immune Markers in Breast Cancer and Chemotherapy Response</title>
		<link>https://bioengineer.org/immune-markers-in-breast-cancer-and-chemotherapy-response/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 06 Aug 2025 10:15:10 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Immune checkpoint molecules in breast cancer]]></category>
		<category><![CDATA[Immune marker prognostic significance]]></category>
		<category><![CDATA[Neoadjuvant chemotherapy response]]></category>
		<category><![CDATA[Precision immunotherapy targets]]></category>
		<category><![CDATA[Tumor microenvironment immunology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/immune-markers-in-breast-cancer-and-chemotherapy-response/</guid>

					<description><![CDATA[In a groundbreaking study that could redefine the landscape of breast cancer treatment, researchers have unveiled critical insights into the expression patterns and clinical significance of several immune checkpoint molecules – CD155, FGL1, Galectin-9, and PD-L1 – in breast cancer patients undergoing neoadjuvant chemotherapy. This comprehensive investigation published in Medical Oncology not only deepens our [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">253827</post-id>	</item>
	</channel>
</rss>
